M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (PD). Three different treatments with M0324 will be studied, M0324 as a monotherapy(Part 1), M0324 in combination with pembrolizumab (Part 2), and in combination with mFOLFIRINOX (a chemotherapy treatment)(Part 3).

Trial Details

NCT ID
NCT07166601
Phase
PHASE1
Sponsor
EMD Serono Research & Development Institute, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • M0324
  • Pembrolizumab
  • mFOLFIRINOX
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • New York, New York, United States|40.71427,-74.00597
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Toronto, Canada|43.65333,-79.38389
  • Chūōku, Japan|33.63867,130.67068

Key Eligibility Criteria

  • Part 1- M0324 Monotherapy:
  • Participants with certain advanced/metastatic solid tumor types known to overexpress MUC-1 and who are intolerant or refractory to standard therapy…
  • Part 2- M0324 Combination with Pembrolizumab:
  • Participants with certain advanced/metastatic tumor types known to overexpress MUC-1 and the participants in the combination treatment involving M0…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →